Advocates for national pharmacare who insist on control of drug prices, not by negotiation but by federal regulation, may have ...
The Appeal Court’s unanimous decision demonstrates that the Patented Medicine Prices Review Board is out of control in an anti-industry, ...
The PMPRB has abused its independence. The functional purpose of the PMPRB is no longer relevant, write Nigel Rawson and ...
OTTAWA, ON (June 3, 2021): The COVID-19 pandemic has unmasked a dangerous lack of investment in pharmaceutical and vaccine research, development, and ...
The COVID-19 pandemic has cost lives and caused much fear in Canada. With Canadians now eagerly waiting for vaccines, Nigel ...
Canadian governments, at all levels, must take responsibility for their inept procurement and distribution processes in their health systems, write ...
Canadians need Ottawa to work with the pharmaceutical industry, clinicians and patients to improve access to new medicines and vaccines, ...
The prime minister has committing to ensuring developing nations get access to the long awaited vaccine, but what is his ...
The federal government is pursuing an aggressive agenda using untried methods to regulate extremely low drug prices, writes Nigel Rawson. ...
OTTAWA, ON (June 18, 2020): The COVID-19 pandemic has revealed numerous weaknesses in Canadian health care, and as the world ...
Unless Ottawa guarantees the price or postpones the PMPRB revisions, manufacturers will not know whether a tendered price is compliant ...
OTTAWA, ON (June 2, 2020): Changes to the Patented Medicine Prices Review Board (PMPRB) have been delayed until January 2021 ...
